» Articles » PMID: 26255629

Mutant P53 Accumulates in Cycling and Proliferating Cells in the Normal Tissues of P53 R172H Mutant Mice

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Aug 11
PMID 26255629
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The tumour suppressor p53 is regulated primarily at the protein level. In normal tissues its levels are maintained at a very low level by the action of specific E3 ligases and the ubiquitin proteosome pathway. The mutant p53 protein contributes to transformation, metastasis and drug resistance. High levels of mutant p53 can be found in tumours and the accumulation of mutant p53 has previously been reported in pathologically normal cells in human skin. We show for the first time that similarly elevated levels of mutant p53 can be detected in apparently normal cells in a mutant p53 knock-in mouse model. In fact, in the small intestine, mutant p53 spontaneously accumulates in a manner dependent on gene dosage and cell type. Mutant p53 protein is regulated similarly to wild type p53, which can accumulate rapidly after induction by ionising radiation or Mdm2 inhibitors, however, the clearance of mutant p53 protein is much slower than wild type p53. The accumulation of the protein in the murine small intestine is limited to the cycling, crypt base columnar cells and proliferative zone and is lost as the cells differentiate and exit the cell cycle. Loss of Mdm2 results in even higher levels of p53 expression but p53 is still restricted to proliferating cells in the small intestine. Therefore, the small intestine of these p53 mutant mice is an experimental system in which we can dissect the molecular pathways leading to p53 accumulation, which has important implications for cancer prevention and therapy.

Citing Articles

Lymph node myeloid sarcoma with TP53‑associated myelodysplastic syndrome: A case report.

Mao M, Deng S Oncol Lett. 2024; 28(1):324.

PMID: 38807682 PMC: 11130743. DOI: 10.3892/ol.2024.14458.


Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo.

Xue Y, Luis B, Dress R, Murad K, Ginhoux F, Barker N Proc Natl Acad Sci U S A. 2023; 120(13):e2219978120.

PMID: 36940336 PMC: 10068759. DOI: 10.1073/pnas.2219978120.


p53 mutation in normal esophagus promotes multiple stages of carcinogenesis but is constrained by clonal competition.

Murai K, Dentro S, Ong S, Sood R, Fernandez-Antoran D, Herms A Nat Commun. 2022; 13(1):6206.

PMID: 36266286 PMC: 9584949. DOI: 10.1038/s41467-022-33945-y.


The Common Germline Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model.

Jeffers J, Pinto E, Rehg J, Clay M, Wang J, Neale G Cancer Res. 2021; 81(9):2442-2456.

PMID: 33637564 PMC: 8137600. DOI: 10.1158/0008-5472.CAN-20-1750.


Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity.

Li Q, Karim R, Cheng M, Das M, Chen L, Zhang C Oncogene. 2020; 39(29):5187-5200.

PMID: 32555331 PMC: 7398576. DOI: 10.1038/s41388-020-1344-y.


References
1.
Sabapathy K, Klemm M, Jaenisch R, Wagner E . Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J. 1997; 16(20):6217-29. PMC: 1326306. DOI: 10.1093/emboj/16.20.6217. View

2.
Lewandoski M, Martin G . Cre-mediated chromosome loss in mice. Nat Genet. 1997; 17(2):223-5. DOI: 10.1038/ng1097-223. View

3.
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef L, Masucci M . Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004; 10(12):1321-8. DOI: 10.1038/nm1146. View

4.
Olive K, Tuveson D, Ruhe Z, Yin B, Willis N, Bronson R . Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119(6):847-60. DOI: 10.1016/j.cell.2004.11.004. View

5.
Lang G, Iwakuma T, Suh Y, Liu G, Rao V, Parant J . Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-72. DOI: 10.1016/j.cell.2004.11.006. View